Efficacy of epidermal growth factor receptor–tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports
Metrics: PDF 977 views | HTML 1315 views | ?
Yongmei Liu1,*, Yan Zhang1,*, Li Zhang2, Bin Liu3, Yongsheng Wang1, Xiaojuan Zhou1, Yanying Li1, Qian Zhao4, Youling Gong1, Lin Zhou1, Jiang Zhu1, Zhenyu Ding1, Jin Wang1, Feng Peng1, Meijuan Huang1, Lu Li1, Li Ren1 and You Lu1
1Department of Thoracic Oncology, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China
2Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China
3Pulmonary Tumor Ward, Sichuan Cancer Hospital, Chengdu, China
4West China School of Medicine, Sichuan University, Chengdu, China
*These authors contributed equally to this work
You Lu, email: email@example.com
Keywords: squamous cell carcinoma, EGFR mutation, epidermal growth factor receptor-tyrosine kinase inhibitor
Received: February 14, 2017 Accepted: May 01, 2017 Published: May 17, 2017
Epidermal growth factor receptor (EGFR) mutations are common in lung adenocarcinoma (ADC) but rare in squamous cell carcinoma (SQC). The efficacy of EGFR-tyrosine kinase inhibitors (EGFR-TKIs) for SQC with EGFR mutations is unclear. The aim of this study was to evaluate the efficacy of EGFR-TKIs for these patients. We performed a retrospective matched-pair case-control study from 3 cancer centers, including 44 SQC and 44 ADC patients with EGFR mutation who were treated with EGFR-TKI. Subsequently, we performed a pooled analysis on the efficacy of EGFR-TKIs for EGFR-mutant SQC in 115 patients, including 71 patients selected from 25 published reports. In our multicenter study, EGFR-mutant SQC and ADC patients had similar objective response rate (ORR) (43.2% vs. 54.5%, p = 0.290), but SQC patients had lower disease control rate (DCR) (71.3% vs. 100%, p = 0.001), significant shorter median progression free survival (PFS) (5.1 vs. 13.0 months, p = 0.000) and median overall survival (OS) (17.2 vs. 23.6 months, p = 0.027). In pooled analysis, the ORR, DCR, PFS and OS of SQC patients were 39.1%, 71.3%, 5.6 months and 15.0 months, respectively. Performance status was the only independent predictor of PFS and erlotinib treatment was associated with a better survival. In conclusion, EGFR-TKI was less effective in EGFR-mutant SQC than in ADC but still has clinical benefit for SQC patients. Further study is need to evaluate the using of EGFR-TKIs in these SQC patients.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.